The RELIEVE-AD study is a prospective, longitudinal cohort survey designed to characterise the patient experience in the clinical practice setting with dupilumab


Patients invited to participate were adults with AD who were prescribed dupilumab in routine clinical practice in the US and then enrolled in the dupilumab patient support program2.

Dupixent provided significant improvements in quality of life, sleep and time without flare and maintained at 36 months compared to baseline

  • 3. Basra M, et al. Dermatology 2015;230:27-33.

    BL, baseline; DLQI, Dermatology Life Quality Index; M, Month; HRQoL, health-related quality of life.
    Total DLQI scores range from 0–30; higher score indicates more impairment to quality of life.

    Rapid and sustained efficacy

    The impact on quality of life significantly improved from baseline (DLQI 14.4/30) to Month 1 (DLQI 5.9/30) and through to Months 0-36 (P<0.001 vs baseline).

    23.9% of patients reported that Atopic Dermatitis had no impact on their life after one month of treatment. This proportion increased to more than half of the patients (52.5%) at 30/36 months.

  • RESULTS: Proportion of patients reporting having no effect from AD on their lives

    23.9% (151/631) of patients reported that their disease had no impact on their life after one month of treatment. This proportion increased to more than half of the patients (52%; 223/425) at 30-36 months.

  • RESULTS: Proportion of patients reporting no flares over the previous 4 weeks

    AD, atopic dermatitis; BL, baseline; M, month.
    All post-treatment initiation time points and imputed ranges were significantly improved from BL (P<0.001).

    Compared with baseline, 33.8% of patients reported no flares on the first month of treatment, and 45.9% reported no flares at Months 30-36 (P<0.001).

  • RESULT: Overall patient satisfaction with current AD treatment(s).

    AD, atopic dermatitis; BL, baseline; M, month.
    Treatment satisfaction was evaluated using a 7-point Likert scale from “extremely satisfied” to “extremely dissatisfied”. Values >3% are shown on columns. All post-treatment initiation time points and imputed ranges were significantly improved from BL (P<0.001).

    After one month of treatment, 85.9% of patients were satisfied with their treatment. This was maintained over 3 years (86.8%).


Adult EASI and IGA

Learn more about how DUPIXENT can help improve AD lesions in adults.




Find out more


Safety Profile

Learn more about safety profile of DUPIXENT.





Find out more

icon


Real-world Experience

Learn more about real-world experience in UK centres.




Find out more

    References

    1. DUPIXENT Summary of Product Characteristics. September 2021.
    2. Bruce Strober, MD, Usha G. Mallya, Min Yang, MD, et al. Treatment Outcomes Associated with Dupilumab Use in Patients with Atopic Dermatitis. 1-Year Results from the RELIEVE-AD Study. JAMA Dermatol. 2022;158(2):142-150. doi:10.1001/jamadermatol.2021.4778.
    3. Basra M, et al. Dermatology 2015;230:27-33.

MAT-XU-2200951(v1.0) | Date of preparation: April 2022